GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Total Noninterest Expense

Shield Therapeutics (LSE:STX) Total Noninterest Expense


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Total Noninterest Expense?

Total Noninterest Expense only applies to banks.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.